Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 YearsBenzinga • 06/21/22
Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious DiseasesGlobeNewsWire • 06/21/22
Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene TherapyGlobeNewsWire • 06/13/22
Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) RecognitionGlobeNewsWire • 05/24/22
Ocugen shares jump premarket after FDA lifts clinical hold on trial of COVID-19 vaccine candidateMarket Watch • 05/23/22
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)GlobeNewsWire • 05/23/22
Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/07/22
Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial ResultsGlobeNewsWire • 05/02/22